Global Hemophilia A Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: Baxalta, Bayer, Biogen - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Hemophilia A - Pipeline Review, H1 2016" report to their offering.

The report provides comprehensive information on the therapeutics under development for Hemophilia A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Hemophilia A
  • The report reviews pipeline therapeutics for Hemophilia A by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report reviews key players involved Hemophilia A therapeutics and enlists all their major and minor projects
  • The report assesses Hemophilia A therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hemophilia A

Companies Mentioned:

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • Apitope International NV
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • DBV Technologies S.A.
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • Expression Therapeutics LLC
  • F. Hoffmann-La Roche Ltd.
  • Green Cross Corporation
  • Idogen AB
  • Lentigen Technology, Inc.
  • mAbxience S.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • SK Chemicals Co., Ltd.
  • Spark Therapeutics, Inc.
  • The International Biotechnology Center (IBC) Generium
  • UniQure N.V.

For more information visit http://www.researchandmarkets.com/research/88vfgt/hemophilia_a

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Hematological Drugs